Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 7:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 572 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Non-Alcoholic Steatohepatitis (NASH) Clear all
Completed Phase 2 Interventional Results available

Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis

NCT03863574
View directory record Official record
Conditions
Non Alcoholic Steatohepatitis
Interventions
Saroglitazar Magnesium 2mg, Saroglitazar Magnesium 4mg, Placebos
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Jackson, Mississippi • Germantown, Tennessee • Hermitage, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 13, 2026, 7:34 PM EDT
Withdrawn No phase listed Observational

Development of Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children

NCT00677183
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis
Interventions
Not listed
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
2 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Oct 13, 2026, 7:34 PM EDT
Completed Not applicable Interventional

Evaluation of the Integrated Radio Frequency Denervation System to Improve Glycemic Control in Type 2 Diabetic Subjects

NCT04285554
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
iRF System Hepatic Denervation
Device
Lead sponsor
Metavention
Industry
Eligibility
22 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Birmingham, Alabama • Stanford, California • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 13, 2026, 7:34 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH

NCT00267670
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, Liver Diseases
Interventions
Pentoxifylline, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 9, 2014 · Synced Oct 13, 2026, 7:34 PM EDT
Terminated Not applicable Interventional

RCT of Caloric Restriction vs. Alternate-Day Fasting in Non-Alcoholic Fatty Liver Disease

NCT03365531
View directory record Official record
Conditions
NAFLD, Obesity, Diabetes Mellitus, Type 2
Interventions
Alternate Daily Fasting (ADF), Caloric Restriction (CR)
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Oct 13, 2026, 7:34 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH.

NCT04019561
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH)
Interventions
MEDI0382 high dose, Placebo for MEDI0382 high dose, MEDI0382 low dose, Placebo for MEDI0382 low dose
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 101 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
26
States / cities
Tucson, Arizona • Canoga Park, California • Chula Vista, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Oct 13, 2026, 7:34 PM EDT
Completed Phase 3 Interventional

A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)

NCT06309992
View directory record Official record
Conditions
Obesity, Non-Alcoholic SteatoHepatitis (NASH)
Interventions
Survodutide, Placebo
Combination Product
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
33
States / cities
Fountain Valley, California • Gardena, California • Long Beach, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 13, 2026, 7:34 PM EDT
Recruiting Phase 3 Interventional

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

NCT06215716
View directory record Official record
Conditions
NASH With Fibrosis, MASH With Fibrosis
Interventions
Efruxifermin, Placebo
Drug
Lead sponsor
Akero Therapeutics, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
198
States / cities
Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 160 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 13, 2026, 7:34 PM EDT
Completed Phase 1 Interventional

A Study to Assess the Pharmacokinetics of PXL770 After 4 Weeks of Treatment in Subjects With NAFLD

NCT03950882
View directory record Official record
Conditions
Nonalcoholic Fatty Liver
Interventions
PXL770, Placebo
Drug
Lead sponsor
Poxel SA
Industry
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 13, 2026, 7:34 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)

NCT03987074
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Semaglutide, Firsocostat, Cilofexor
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
18
States / cities
Chandler, Arizona • Coronado, California • La Jolla, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Oct 13, 2026, 7:34 PM EDT
Terminated No phase listed Observational

Utilization of MAsS in Patients Undergoing LT for HCC

NCT05184283
View directory record Official record
Conditions
NAFLD, Hepatocellular Carcinoma, Liver Diseases, Liver Cancer, Cirrhosis, Liver, Hepatitis C
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Oct 13, 2026, 7:34 PM EDT
Completed Phase 3 Interventional

Development of a Breath Test for Monitoring Patients With Liver Disease

NCT00244569
View directory record Official record
Conditions
Fatty Liver, Cirrhosis
Interventions
13C-Methacetin, Breath ID Machine
Drug · Device
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 13, 2026, 7:34 PM EDT
Completed Phase 1 Interventional

ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)

NCT05006885
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
ALT-801, Placebo
Drug · Other
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Scottsdale, Arizona • Tucson, Arizona • Montclair, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 13, 2026, 7:34 PM EDT
Terminated Phase 2 Interventional Results available

Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the US

NCT05211284
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease
Interventions
Saroglitazar Magnesium 4 mg, Placebo
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 13, 2026, 7:34 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of FT 4101 in Overweight/Obese Participants With Non-alcoholic Steatohepatitis

NCT04004325
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH), Overweight or Obesity
Interventions
FT-4101, FT-4101 placebo, Deuterated Water
Drug · Other
Lead sponsor
Forma Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Chula Vista, California • Montclair, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 13, 2026, 7:34 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis

NCT04669158
View directory record Official record
Conditions
Non Alcoholic Steatohepatitis, Fibrosis
Interventions
Idebenone, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Redwood City, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 13, 2026, 7:34 PM EDT
Not listed Phase 2 Interventional

A Study to Assess ARI-3037MO on Hepatic Fat Metabolism in Patients With Dysglycemia and Evidence of Hepatic Steatosis

NCT02574325
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Placebo, ARI-3037MO
Drug
Lead sponsor
Arisaph Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 8, 2016 · Synced Oct 13, 2026, 7:34 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Diet and Meal Timing in Patients With Metabolic Dysfunction Associated Steatoic Liver Disease

NCT05332613
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
TRE plus SOC, SOC, TRE
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 13, 2026, 7:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Intra-Individual Reproducibility of the Non-Invasive Assessment of the Portal Circulation

NCT01579162
View directory record Official record
Conditions
Hepatitis C, Chronic, Non-Alcoholic Fatty Liver Disease
Interventions
Cholate-24-13C (IND 65121) & Cholate-2,2,4,4-d4 (IND 65123)
Device
Lead sponsor
HepQuant, LLC
Industry
Eligibility
22 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Oct 13, 2026, 7:34 PM EDT
Completed Not applicable Interventional Results available

Effects of Pitavastatin on Insulin Sensitivity and Liver Fat

NCT02290106
View directory record Official record
Conditions
Obesity, Fatty Liver, Nonalcoholic
Interventions
pitavastatin, PLACEBO
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 65 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 2, 2019 · Synced Oct 13, 2026, 7:34 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis

NCT03421431
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis
Interventions
EDP-305 Dose 1, EDP-305 Dose 2, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
70
States / cities
Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 13, 2026, 7:34 PM EDT
Completed Phase 2 Interventional

Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH

NCT06104319
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
GSK4532990
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
14
States / cities
Chula Vista, California • Montclair, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 13, 2026, 7:34 PM EDT
Completed Phase 4 Interventional

Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH)

NCT00160407
View directory record Official record
Conditions
Fatty Liver, Hepatitis
Interventions
Orlistat (Xenical), 1400 kcal diet (30% fat)
Drug · Behavioral
Lead sponsor
St. Louis University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
2
States / cities
St Louis, Missouri • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 20, 2007 · Synced Oct 13, 2026, 7:34 PM EDT
Not listed Phase 1 Interventional

Fecal Microbiota Transplantation (FMT) in Nonalcoholic Steatohepatitis(NASH). A Pilot Study

NCT02469272
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease
Interventions
Fecal Microbiota Transplantation
Drug
Lead sponsor
Lifespan
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 1, 2017 · Synced Oct 13, 2026, 7:34 PM EDT